6 Einträge gefunden

1. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma

   1. Mateos, Maria-Victoria
   2. Weisel, Katja
   3. De Stefano, Valerio
   4. Goldschmidt, Hartmut
   5. Delforge, Michel
   6. Mohty, Mohamad
   7. Cavo, Michele

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
2. MM-183 CARTITUDE-2 Cohort A: Updated Clinical Data and Biological Correlative Analyses of Ciltacabtagene Autoleucel (cilta-cel) in Lenalidomide-Refractory Patients With Progressive Multiple Myeloma (MM) After 1-3 Prior Lines of Therapy (LOT)

   1. Hillengass, Jens
   2. Cohen, Adam D
   3. Delforge, Michel
   4. Einsele, Hermann
   5. Goldschmidt, Hartmut
   6. Weisel, Katja
   7. Raab, Marc-Steffen

   2022 - Forschungsinformationssystem des UKE
3. Carfilzomib 56 mg/m2 twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with bortezomib and dexamethasone (DVd): a matching-adjusted indirect treatment comparison

   1. Weisel, Katja
   2. Nooka, Ajay K
   3. Terpos, Evangelos
   4. Spencer, Andrew
   5. Goldschmidt, Hartmut
   6. Dirnberger, Franziska
   7. DeCosta, Lucy

   2022 - Forschungsinformationssystem des UKE
4. MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial

   1. Raab, Marc S
   2. Engelhardt, Monika
   3. Blank, Antje
   4. Goldschmidt, Hartmut
   5. Agis, Hermine
   6. Blau, Igor W
   7. Einsele, Hermann

   2020 - Forschungsinformationssystem des UKE
5. Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials

   1. Weisel, Katja
   2. Majer, Istvan
   3. DeCosta, Lucy
   4. Oriol, Albert
   5. Goldschmidt, Hartmut
   6. Ludwig, Heinz
   7. Campioni, Marco

   2020 - Forschungsinformationssystem des UKE
6. Health-related quality of life of carfilzomib- and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma, based on German benefit assessment data

   1. Weisel, Katja
   2. Ludwig, Heinz
   3. Rieth, Achim
   4. Lebioda, Andrea
   5. Goldschmidt, Hartmut

   2020 - Forschungsinformationssystem des UKE